Macquarie Group Ltd. grew its position in shares of Epizyme (NASDAQ:EPZM) by 100.7% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 82,485 shares of the biopharmaceutical company’s stock after purchasing an additional 41,385 shares during the period. Macquarie Group Ltd. owned approximately 0.12% of Epizyme worth $1,035,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Teacher Retirement System of Texas bought a new stake in shares of Epizyme in the fourth quarter worth $202,000. Fox Run Management L.L.C. increased its stake in shares of Epizyme by 64.7% in the fourth quarter. Fox Run Management L.L.C. now owns 19,275 shares of the biopharmaceutical company’s stock worth $242,000 after buying an additional 7,575 shares during the last quarter. Bailard Inc. bought a new stake in shares of Epizyme in the fourth quarter worth $251,000. Virtus Fund Advisers LLC bought a new stake in shares of Epizyme in the fourth quarter worth $346,000. Finally, American International Group Inc. increased its stake in shares of Epizyme by 19.3% in the fourth quarter. American International Group Inc. now owns 32,998 shares of the biopharmaceutical company’s stock worth $414,000 after buying an additional 5,334 shares during the last quarter. Institutional investors own 85.88% of the company’s stock.
In other Epizyme news, COO Matthew Ros sold 72,264 shares of Epizyme stock in a transaction on Monday, February 5th. The shares were sold at an average price of $16.63, for a total value of $1,201,750.32. Following the completion of the transaction, the chief operating officer now owns 74,867 shares of the company’s stock, valued at $1,245,038.21. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 25.20% of the company’s stock.
Epizyme stock opened at $14.85 on Friday. The firm has a market capitalization of $1,135.35, a price-to-earnings ratio of -6.81 and a beta of 1.96. Epizyme has a 12 month low of $9.30 and a 12 month high of $21.40.
Epizyme (NASDAQ:EPZM) last released its quarterly earnings data on Tuesday, March 13th. The biopharmaceutical company reported ($0.52) EPS for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.05. The company’s revenue was down 100.0% compared to the same quarter last year. equities analysts forecast that Epizyme will post -2.37 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This story was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this story on another publication, it was illegally stolen and republished in violation of U.S. and international copyright legislation. The correct version of this story can be read at https://www.tickerreport.com/banking-finance/3340451/macquarie-group-ltd-has-1-04-million-stake-in-epizyme-epzm.html.
Epizyme, Inc, a clinical stage biopharmaceutical company, discovers and develops novel epigenetic medicines for patients with cancer and other diseases in the United States. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial in elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function,; and Phase Ib/II clinical trial for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer, as well as Phase II clinical trial in adult patients with ovarian cancer.
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.